Knee Replacement Surgery — Cost, Top Hospitals & Success Rates | MyMedicPlus

Knee replacement surgery, formally known as total knee arthroplasty (TKA) or knee joint replacement, is one of the most successful and commonly performed orthopaedic procedures worldwide. The operation involves removing damaged cartilage and a thin layer of underlying bone from the ends of the femur (thighbone), tibia (shinbone), and often the patella (kneecap), and replacing them with precision-engineered metal and high-grade polyethylene (plastic) implant components that mimic the smooth gliding function of a healthy knee.

According to the AAOS, approximately 790,000 total knee replacements are performed annually in the United States alone, with global numbers exceeding 2 million per year. The surgery has a well-established track record: studies from national joint registries show that more than 90% of implants survive for 15 years and over 80% for 20 years.

The surgery does not simply relieve pain — it restores joint mechanics, corrects leg alignment, and enables patients to return to an active life. Most patients describe it as life-changing, particularly those who had been severely limited by pain for years.

Knee replacement is indicated when the articular cartilage — the smooth cushioning tissue covering the ends of the knee bones — is substantially destroyed by arthritis or injury to the point where non-surgical treatments no longer provide adequate relief.

Knee replacement surgery addresses end-stage joint disease in which the knee cartilage is irreversibly damaged:

• Osteoarthritis (OA): The most common indication, accounting for over 90% of knee replacements. Progressive loss of articular cartilage leads to bone-on-bone contact, severe pain, stiffness, and deformity (varus or valgus). OA is primarily age-related but accelerated by obesity, prior joint injury, and genetics.
• Rheumatoid arthritis (RA): A chronic autoimmune disease that causes synovial inflammation, cartilage erosion, and bone destruction across multiple joints. Despite improved disease-modifying drug therapies, end-stage RA frequently requires joint replacement.
• Post-traumatic arthritis: Severe fractures involving the knee joint surface (tibial plateau, femoral condyle, patella) can accelerate cartilage degeneration, resulting in post-traumatic OA that may require replacement years after the original injury.
• Avascular necrosis (AVN) of the femoral condyle: Disruption of blood supply to the bone can cause condylar collapse and secondary arthritis, necessitating replacement when the defect is large.
• Gout and calcium pyrophosphate deposition (CPPD): Chronic crystal arthropathy can lead to irreversible joint damage in severe, long-standing cases.
• Failed previous knee surgery: Prior high tibial osteotomy, unicompartmental replacement, or meniscal surgery that has not achieved durable relief may be converted to total knee replacement.

Knee replacement is considered when the following criteria are met:

• Radiological evidence of advanced arthritis: X-rays demonstrating joint space narrowing (Kellgren-Lawrence grade 3–4), osteophytes, subchondral sclerosis, or bone-on-bone contact.
• Significant functional limitation: Pain severe enough to limit daily activities (walking, climbing stairs, getting up from a chair) and substantially reduce quality of life.
• Failure of conservative management: An adequate trial (typically 3–6 months) of NSAIDs, physiotherapy, corticosteroid injections, activity modification, weight loss, and walking aids has not provided sufficient relief.
• Age and bone quality: Most commonly performed in adults over 50–55 years. Younger patients (under 50) are counselled about potential implant longevity concerns and higher revision rates, though modern implants perform increasingly well in this group. There is no absolute upper age limit if the patient is medically fit.
• BMI considerations: Obesity (BMI >40) significantly increases complication risk (infection, implant failure). Patients are strongly encouraged to lose weight before surgery where feasible; some centres require a BMI below 40 or 45 before proceeding.
• Absence of active infection: Active local or systemic infection is an absolute contraindication. A dental review is completed before surgery to eliminate any potential sources of haematogenous seeding of the implant.
• Medical optimisation: Diabetes control (HbA1c ideally below 8%), cardiovascular risk assessment, anticoagulation bridging plan, iron supplementation for anaemia, and smoking cessation are all addressed pre-operatively.

Several types of knee replacement procedures are available, selected based on the pattern and extent of arthritis:

• Total knee replacement (TKR): All three compartments of the knee (medial, lateral, patellofemoral) are resurfaced with implants consisting of a femoral metal component, a tibial metal tray with a polyethylene insert, and an optional patellar component. This is the most common and most studied type.
• Unicompartmental (partial) knee replacement (UKR): Only the affected compartment (most commonly the medial compartment) is replaced. Bone and ligament preservation, faster recovery, and a more natural feel are advantages. Suitable for 15–20% of knee replacement candidates. Long-term outcomes are comparable to TKR in carefully selected patients.
• Patellofemoral replacement: Resurfaces only the articulation between the patella and femoral trochlea — used for isolated patellofemoral arthritis with preserved medial and lateral compartments.
• Bilateral simultaneous knee replacement: Both knees replaced in a single anaesthetic session. Reduces total time under anaesthesia versus two separate procedures but carries higher cardiopulmonary risk. Typically offered to otherwise healthy patients with bilateral severe disease.
• Revision knee replacement: Replacement of a failed or worn-out primary implant. More complex than primary TKR due to bone loss, scarring, and need for specialised revision implants with stems and augments.
• Computer-assisted and robotic-assisted TKR: Advanced navigation and robotic arm systems (e.g., Mako robotic-arm surgery) improve precision of bone cuts and component alignment, potentially reducing outliers and improving long-term implant survival. Increasingly available at leading centres globally.

Knee replacement surgery offers substantial, durable improvements in quality of life:

• Pain relief: Approximately 90–95% of patients report significant reduction in knee pain at one year. The relief is typically dramatic for end-stage OA patients who had been in severe chronic pain.
• Restored function and mobility: Most patients return to walking without a stick at 6–8 weeks and resume activities such as swimming, cycling, and social dancing within 3–6 months.
• Long implant lifespan: Modern cemented cobalt-chrome/polyethylene implants last 15–25 years in the majority of patients. National registry data from Sweden and Australia (the oldest and largest in the world) report 95% survival at 10 years and 90% at 15 years.
• Improved leg alignment: Deformities (varus bow-leg, valgus knock-knee) caused by eccentric cartilage loss are corrected at surgery, redistributing load evenly across the joint.
• Reduced cardiovascular risk: Restoring mobility after knee replacement is associated with improved physical activity levels, contributing to better metabolic and cardiovascular health long-term.
• Psychological wellbeing: Chronic pain is strongly associated with depression and social withdrawal. Pain relief and restored independence after TKR are associated with significant improvements in mental health and social participation.

Knee replacement carries both general surgical risks and implant-specific complications:

• Periprosthetic joint infection (PJI): The most feared complication, occurring in 1–2% of primary TKRs. PJI often requires two-stage revision surgery (removal of the infected implant, antibiotic spacer placement, and re-implantation after infection clearance). Strict aseptic technique, antibiotic prophylaxis, and patient optimisation minimise but do not eliminate this risk.
• Deep vein thrombosis (DVT) and pulmonary embolism (PE): Major knee surgery triggers a prothrombotic state. Venous thromboembolism (VTE) prophylaxis with low-molecular-weight heparin, rivaroxaban, or aspirin is standard for 2–6 weeks post-operatively, combined with mechanical compression and early mobilisation.
• Stiffness (arthrofibrosis): 5–10% of patients develop limited range of motion due to excessive scar tissue. Intensive physiotherapy, manipulation under anaesthesia (MUA), or rarely revision surgery may be required.
• Implant loosening and aseptic failure: Long-term mechanical failure of the cement-bone or bone-implant interface leads to pain and instability requiring revision. Risk increases with obesity, high-impact activities, and younger age.
• Periprosthetic fracture: Fracture around the implant (typically femoral condyle or tibial plateau) may result from trauma or bone loss. Requires surgical fixation or revision.
• Nerve injury: The peroneal nerve is at risk in valgus deformity correction; common peroneal palsy (foot drop) occurs in approximately 0.3–1% of cases.
• Persistent pain: 10–20% of patients report residual pain at one year that does not meet their expectations. Complex regional pain syndrome (CRPS), undiagnosed spinal pathology, or hip pathology can contribute.

Recovery from total knee replacement follows a structured, milestone-based timeline:

• Day 0–1: Most patients begin physiotherapy-guided walking with a walking frame on the day of surgery or the morning after. Pain is managed with a multimodal analgesic protocol (paracetamol, NSAIDs, nerve blocks, short-course opioids).
• Days 2–4: Supervised stair climbing, range of motion exercises, and weaning from walking frame to crutches. Most patients are discharged from hospital with a home physiotherapy plan and VTE prophylaxis medication.
• Weeks 1–6: Daily home exercises focusing on knee extension and flexion. Walking distance gradually increases. Driving resumes at 4–6 weeks (right knee) when the patient can perform emergency braking safely and is off strong opioids.
• Weeks 6–12: Outpatient physiotherapy or gym-based rehabilitation. Swimming and cycling are usually permitted at 6–8 weeks.
• Months 3–6: Return to low-impact sports (golf, hiking, cycling). Most patients describe meaningful quality-of-life improvement by 3 months.
• Months 6–12: Full functional recovery. Maximum achievable range of motion is typically established. Residual swelling gradually resolves.

Follow-up appointments are scheduled at 6 weeks, 3 months, 1 year, and then every 2–5 years lifelong. Routine X-rays monitor implant position and signs of loosening. Patients should notify their surgeon immediately if they develop sudden pain, swelling, warmth, or fever at any time — these signs may indicate PJI.

Knee replacement costs vary dramatically by country, driven primarily by implant pricing, hospital fees, and system economics:

• India: USD 5,000–10,000 for primary TKR (all-inclusive at major private hospitals). India is among the leading medical tourism destinations for joint replacement, with JCI-accredited hospitals offering internationally trained surgeons at a fraction of Western costs.
• Thailand and Malaysia: USD 8,000–14,000. High-quality private hospitals in Bangkok and Kuala Lumpur offer comparable outcomes to Western centres.
• Turkey: USD 7,000–12,000. Growing medical tourism hub with competitive pricing and modern facilities.
• United States: USD 30,000–50,000 (uninsured, out-of-pocket). With Medicare or private insurance, patient out-of-pocket costs vary by plan deductible and coinsurance.
• United Kingdom (private): GBP 12,000–18,000 (USD 15,000–22,000). NHS waiting times have driven significant private demand.
• Australia (private): AUD 20,000–35,000 (USD 13,000–23,000) after private health insurance rebates.
• Cost influencers: Implant brand and grade (standard vs. premium), robotic-assisted vs. conventional surgery (adds USD 2,000–5,000), bilateral vs. unilateral, revision vs. primary, post-operative rehabilitation package length, and length of inpatient stay all affect total cost.

In countries with universal healthcare (UK NHS, Canada, Australia, most of Europe), primary knee replacement for medically indicated OA is covered, though access may be tiered by severity and waiting lists can be significant (6–24 months in some systems).

Knee replacement is appropriate for end-stage disease but should be considered only after exhausting or properly trialling non-surgical and less invasive options:

• Weight loss: Each kilogram of body weight reduction decreases knee-loading force by approximately 4 kg. In overweight patients, significant weight loss can meaningfully delay or avoid the need for replacement.
• Physiotherapy and exercise: A structured programme targeting quadriceps and hip abductor strengthening is supported by strong evidence as the primary treatment for mild to moderate OA. Results from the ESCAPE trial show outcomes comparable to arthroscopy for many patients.
• Intra-articular injections: Corticosteroid injections offer short-term (weeks to months) pain relief. Hyaluronic acid (viscosupplementation) has modest evidence of benefit. PRP (platelet-rich plasma) is an emerging option with promising early data.
• Opioid and NSAID analgesia: Acceptable for short-term management but not recommended for long-term use due to adverse effects (renal, gastrointestinal, cardiovascular, addiction risk).
• High tibial osteotomy (HTO): Corrects varus (bow-leg) alignment by cutting and realigning the tibia, shifting load away from the diseased medial compartment. Suitable for younger, active patients with unicompartmental OA and significant deformity.
• Unicompartmental knee replacement (UKR): Where only one compartment is diseased, a partial replacement (bone-preserving, faster recovery) is an intermediate option between arthroscopy and full TKR.